Symbols

MBX

MBX Biosciences·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MBX

Mbx Biosciences, Inc.

A clinical-stage biopharmaceutical company focused on discovering and developing novel precision peptide therapeutics for the treatment of endocrine and metabolic diseases

Industry

Pharmaceutical

Established Date

Listing Date

09/13/2024

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.mbxbio.com

Security Type

Common stock

Office address

11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032

Business

Introduction

MBX Biosciences, Inc., was incorporated as an Indiana limited liability company in August 2018 and transformed into a Delaware corporation in April 2019. The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for endocrine and metabolic diseases. Its R&D pipeline includes drug candidates for hypoparathyroidism, obesity and postbariatric hypoglycemia designed using its proprietary Precision Endocrine Peptide Platform.

Company Financials

EPS

MBX has released its 2025 Q4 earnings. EPS was reported at -0.49, versus the expected -0.63, beating expectations. The chart below visualizes how MBX has performed over recent quarters, highlighting trends in earnings surprises.